Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
99,876
52-wk High
$1.39
52-wk Low
$0.38

Select another date:

Tue, Nov 28 2017

UPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped

* Shares plummet >50 pct to $0.38 (Adds background, details on Auris' pipeline; updates shares)

BRIEF-Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS

Auris Medical to abandon hearing-loss drug trial

Nov 28 Auris Medical Holding AG said on Tuesday it would terminate a late-stage study testing its drug to treat sudden deafness after the company's lead drug failed to improve hearing ability in patients in another study.

BRIEF-Auris Medical Reports Q3 Loss Per Share CHF 0.14

* AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common shares

* Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc‍​ - SEC Filing Source text: (http://bit.ly/2ggfWjL) Further company coverage:

BRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital Fund

* Auris Medical announces share purchase agreements with Lincoln Park Capital Fund, Llc

BRIEF-Auris Medical announces transfer to Nasdaq capital market

* Auris Medical Holding AG - co's shares will continue to trade uninterrupted under symbol "EARS."​

BRIEF-Auris Medical provides board of directors update

* Auris Medical Holding Ag - ‍announced resignation of antoine papiernik as a member of board of directors due to disagreement with board​

BRIEF-Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitus

* Auris Medical completes patient recruitment for phase 3 TACTT3 trial of Keyzilen in acute and post-acute tinnitus

BRIEF-Auris Medical posts Q2 loss per share CHF 0.12

* Auris Medical provides business update and reports second quarter 2017 financial results

Select another date: